Cozadd Bruce C's Form 4 filing
Jazz Pharmaceuticals plc (JAZZ) · filed Mar 3, 2022
- Accession no.
- 0001765581-22-000011
- Filed
- Mar 3, 2022
- Trade date
- Mar 1-2, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.79M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cozadd Bruce CCIK 0001193210 | Director, Officer (Chairman & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2022 | Ordinary Shares | MOption exerciseAcquired | +9,700 | $46.83 | +$454,251 | 335,488 | Direct | |
| Mar 1, 2022 | Ordinary Shares | SSaleDisposed | −3,260 | $135.73F2 | −$442,479.8 | 332,228 | Direct | |
| Mar 1, 2022 | Ordinary Shares | SSaleDisposed | −3,041 | $136.73F3 | −$415,795.93 | 329,187 | Direct | |
| Mar 1, 2022 | Ordinary Shares | SSaleDisposed | −200 | $137.40F4 | −$27,480 | 328,987 | Direct | |
| Mar 2, 2022 | Ordinary Shares | SSaleDisposed | −6,000 | $150.00 | −$900,000 | 322,987 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2022 | Ordinary Shares | MOption exerciseDisposed | −9,700 | $0.00 | $0 | 48,432 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.18 to $136.12. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F3
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $136.18 to $137.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F4
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.255 to $137.44. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.